BUY
CMP: Rs3860 |
Target Price: Rs4150
* Q3FY22 revenue exceeded our expectation, while EBITM missed the estimate. Revenue grew 3.9%/15.4% QoQ/YoY in CC terms. EBITM declined by ~60bps QoQ to 25%, due to an increase in compensation costs, higher subcontracting expenses and discretionary non-manpower costs.
* Revenue growth was broad-based, and all verticals posted double-digit CC growth YoY. Growth was led by Retail & CPG (20.4% CC YoY), Manufacturing (18.3%), BFSI (17.9%), Technology & Services (17.7%) and Life Sciences & Healthcare (16.3%). All geographies, except for Asia Pacific and MEA, posted double-digit growth YoY.
* A strong and sustained demand environment, broad-based growth, healthy deal intake (USD23.3bn in 9MFY22), and traction in cloud, IoT and Digital engineering give management confidence to sustain a robust revenue growth trajectory.
* We tweak our FY22/23/24 EPS estimates by -1.5%/0.5%/0.2% after factoring in the Q3 performance and buyback. We maintain Buy with a TP of Rs4,150 (Rs4,100 earlier) at 30x Dec'23E EPS, considering steady deal wins and consistent execution.
No comments:
Post a Comment